文献速递头颈外科

术中电子束放疗治疗局部区域持续或复发头颈癌

Intraoperative electron beam radiotherapy for locoregionally persistent or recurrent head and neck cancer.
PubMed 文献 · Head Neck · 2019-02-19

本研究回顾性分析61例接受挽救性手术联合术中放疗的持续或复发头颈癌患者,58例(95%)既往接受过外照射放疗,44例(72%)为鳞状细胞癌,28例(46%)手术切缘阳性,术中放疗中位剂量12.5 Gy(范围10-17.5),23例(38%)术后接受外照射放疗(中位45 Gy)。中位无进展生存期和总生存期分别为9.8和19.1个月,1年和2年局部区域控制率分别为59%和35%,非鳞状细胞癌组织学总生存期更优(P = .03),鳞状细胞癌患者中阴性手术切缘与无进展生存期(P = .09)和总生存期(P = .06)改善呈趋势相关,发生1例因颈动脉破裂导致的5级毒性。

要点

  • 术中放疗中位剂量12.5 Gy(范围10-17.5),联合挽救性手术治疗持续或复发头颈癌。
  • 中位无进展生存期9.8个月,中位总生存期19.1个月,1年局部区域控制率59%。
  • 非鳞状细胞癌组织学总生存期更优(P = .03),鳞状细胞癌中阴性切缘与生存改善呈趋势相关。

核心结论

  • 术中放疗在本机构显示出有效的局部区域控制和总生存期,且严重毒性发生率可接受。
  • 非鳞状细胞癌组织学总生存期显著更优(P = .03)。
  • 鳞状细胞癌患者中,阴性手术切缘与无进展生存期(P = .09)和总生存期(P = .06)改善呈趋势相关。

研究设计与样本

  • 回顾性分析61例接受挽救性手术联合术中放疗的持续或复发头颈癌患者。
  • 58例(95%)既往接受过外照射放疗作为根治性治疗组成部分。
  • 44例(72%)为鳞状细胞癌,28例(46%)手术切缘阳性。
  • 术中放疗中位剂量12.5 Gy(范围10-17.5),23例(38%)术后接受外照射放疗(中位45 Gy)。
  • 采用log-rank检验进行单变量分析,将临床结局与组织学、手术切缘和辅助治疗相关联。

主要发现

  • 存活患者中位随访时间15.9个月。
  • 中位无进展生存期9.8个月,中位总生存期19.1个月。
  • 1年和2年局部区域控制率分别为59%和35%。
  • 1年和2年无进展生存率分别为39%和19%。
  • 1年和2年总生存率分别为62%和42%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To report our institutional experience with intraoperative radiotherapy for persistent or recurrent head and neck cancer. METHODS: Sixty-one patients were treated with salvage surgery and intraoperative radiation therapy (IORT). Fifty-eight patients (95%) had previously received external beam radiotherapy (EBRT) as a component of their definitive therapy. Forty-four patients (72%) had squamous cell carcinoma (SCC). Surgical margins were positive in 28 patients (46%). IORT was prescribed to a median dose of 12.5 Gy (range, 10-17.5). Twenty-three patients (38%) received a course of postoperative EBRT (median 45 Gy). Clinical outcomes were retrospectively reviewed and univariate analysis was performed using log-rank tests to correlate clinical outcomes with histology, surgical margin, and adjuvant therapy. RESULTS: Median follow-up among surviving patients was 15.9 months. Median progression-free survival (PFS) and overall survival (OS) were 9.8 and 19.1 months, respectively. One- and 2-year rates of locoregional control (LRC) were 59% and 35%, respectively. One- and 2-year rates of PFS were 39% and 19%, respectively. One- and 2-year rates of OS were 62% and 42%, respectively. Overall survival was better for non-SCC histology (P = .03). For SCC patients, negative surgical margin showed a trend toward improved PFS (P = .09) and OS (P = .06). There was one grade-5 toxicity due to carotid rupture. CONCLUSIONS: IORT has shown effective LRC and OS with an acceptably low rate of severe toxicity at our institution. OS was significantly better for non-SCC histology. For SCC patients, there is a trend toward improved PFS and OS associated with negative surgical margins.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Wald P, Grecula J, Walston S, et al. Intraoperative electron beam radiotherapy for locoregionally persistent or recurrent head and neck cancer. Head Neck. 2019. PMID: 30779458. doi:10.1002/hed.25673

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。